دورية أكاديمية
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
| العنوان: | Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea. |
|---|---|
| المؤلفون: | Shin HD; Department of Gastroenterology, Dankook University College of Medicine, Cheonan, Korea., Song IH; Department of Gastroenterology, Dankook University College of Medicine, Cheonan, Korea., Lee SH; Department of Gastroenterology, Soonchunhyang University College of Medicine, Cheonan, Korea., Kim HS; Department of Gastroenterology, Soonchunhyang University College of Medicine, Cheonan, Korea., Lee TH; Department of Gastroenterology, Konyang University College of Medicine, Daejeon, Korea., Eun HS; Department of Gastroenterology, Chungnam University College of Medicine, Daejeon, Korea., Kim SH; Department of Gastroenterology, Chungnam University College of Medicine, Daejeon, Korea., Lee BS; Department of Gastroenterology, Chungnam University College of Medicine, Daejeon, Korea., Chae HB; Department of Gastroenterology, Chungbuk University College of Medicine, Cheongju, Korea., Kim SH; Department of Gastroenterology, College of Medicine, The Catholic University of Korea, Daejeon, Korea., Song MJ; Department of Gastroenterology, College of Medicine, The Catholic University of Korea, Daejeon, Korea., Ko SY; Department of Gastroenterology, Konkuk University College of Medicine, Chungju, Korea., Kim SB; Department of Gastroenterology, Dankook University College of Medicine, Cheonan, Korea. |
| المصدر: | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi [Korean J Gastroenterol] 2024 Mar 25; Vol. 83 (3), pp. 111-118. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Korean Society of Gastroenterology Country of Publication: Korea (South) NLM ID: 101189416 Publication Model: Print Cited Medium: Internet ISSN: 2233-6869 (Electronic) Linking ISSN: 15989992 NLM ISO Abbreviation: Korean J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Seoul, Korea : Korean Society of Gastroenterology, [2003]- |
| مواضيع طبية MeSH: | Hepatitis C, Chronic*/drug therapy , Liver Neoplasms*/drug therapy , Sulfonamides* , Pyrrolidines* , Fluorenes* , Quinoxalines* , Aminoisobutyric Acids* , Benzimidazoles* , Lactams, Macrocyclic* , Cyclopropanes*, Leucine/*analogs & derivatives , Proline/*analogs & derivatives, Humans ; Male ; Sofosbuvir/therapeutic use ; Antiviral Agents/therapeutic use ; Hepacivirus/genetics ; Retrospective Studies ; Treatment Outcome ; Genotype ; Drug Therapy, Combination |
| مستخلص: | Background/aims: This study compared the effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) in real-life clinical practice. Methods: The data from genotype 1 or 2 chronic hepatitis C patients treated with GLE/PIB or sofosbuvir + ribavirin or SOF/LDV in South Korea were collected retrospectively. The analysis included the treatment completion rate, sustained virologic response at 12 weeks (SVR12) test rate, treatment effectiveness, and adverse events. Results: Seven hundred and eighty-two patients with genotype 1 or 2 chronic hepatitis C who were treated with GLE/PIB (n=575) or SOF/LDV (n=207) were included in this retrospective study. The baseline demographic and clinical characteristics revealed significant statistical differences in age, genotype, ascites, liver cirrhosis, and hepatocellular carcinoma between the GLE/PIB and SOF/LDV groups. Twenty-two patients did not complete the treatment protocol. The treatment completion rate was high for both regimens without statistical significance (97.7% vs. 95.7%, p=0.08). The overall SVR12 of intention-to-treat analysis was 81.2% vs. 80.7% without statistical significance (p=0.87). The overall SVR12 of per protocol analysis was 98.7% vs. 100% without statistical significance (p=0.14). Six patients treated with GLE/PIB experienced treatment failure. They were all male, genotype 2, and showed a negative hepatitis C virus RNA level at the end of treatment. Two patients treated with GLE/PIB stopped medication because of fever and abdominal discomfort. Conclusions: Both regimens had similar treatment completion rates, effectiveness, and safety profiles. Therefore, the SOF/LDV regimen can also be considered a viable DAA for the treatment of patients with genotype 1 or 2 chronic hepatitis C. |
| فهرسة مساهمة: | Keywords: Chronic hepatitis C; Glecaprevir; Harvoni; Korea; Pibrentasvir |
| المشرفين على المادة: | 0 (ledipasvir, sofosbuvir drug combination) WJ6CA3ZU8B (Sofosbuvir) K6BUU8J72P (glecaprevir) 013TE6E4WV (ledipasvir) 0 (Antiviral Agents) 2WU922TK3L (pibrentasvir) 0 (Sulfonamides) 0 (Pyrrolidines) 0 (Fluorenes) 0 (Quinoxalines) 0 (Aminoisobutyric Acids) 0 (Benzimidazoles) 0 (Lactams, Macrocyclic) 0 (Cyclopropanes) GMW67QNF9C (Leucine) 9DLQ4CIU6V (Proline) |
| تواريخ الأحداث: | Date Created: 20240324 Date Completed: 20240326 Latest Revision: 20240326 |
| رمز التحديث: | 20240326 |
| DOI: | 10.4166/kjg.2023.141 |
| PMID: | 38522854 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2233-6869 |
|---|---|
| DOI: | 10.4166/kjg.2023.141 |